PubMed
MOTS-c is an ancient mitochondrial-encoded regulator of metabolic homeostasis
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015
Compare
MOTS-c vs Tirzepatide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
MOTS-c
113 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 18% · Mixed 2% · Unfavorable overall 80%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
230
Energy
47
Recovery
3
Mood
2
Cognition
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
191
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 5+ mg
Reports span 0.01 to ≥ 5 mg (open-ended top bucket)
0.01–0.025 mg
4
0.1–0.2 mg
1
0.2–0.4 mg
8
0.4–0.6 mg
11
0.6–1 mg
8
1–2 mg
42
2–3 mg
45
3–5 mg
7
5+ mg
107
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 56% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 44 days · Based on 45 repeat reporters
Tirzepatide
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
7
Sleep
1
Mood
1
Energy
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Injection site irritation
3
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
0.4–0.6 mg
1
5+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Sources (14)
Published sources linked on the MOTS-c and Tirzepatide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
MOTS-c: A mitochondrial-encoded peptide regulating muscle function
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021
- Wiki study page →Source
PubMed
MOTS-c improves insulin sensitivity in mice and humans
Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019
- Wiki study page →Source
ClinicalTrials.gov
MOTS-c metabolic studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023
- Wiki study page →Source
PubMed
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016
- Wiki study page →Source
FDA Drug Label
MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli Lilly. FDA Drug Label. 2022
- Wiki study page →Source
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022
- Wiki study page →Source
ClinicalTrials.gov
Tirzepatide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021
- Wiki study page →Source
PubMed
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024
- Wiki study page →Source
FDA Drug Label
ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli Lilly. FDA Drug Label. 2023
- Wiki study page →Source
PubMed
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023
- Wiki study page →Source
PubMed
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025